Clinical Trials on Plaque Psoriasis Vulgaris

Total 3723 results

Centre of Evidence of the French Society of Dermatology

Recruiting

Systemic Treatment of Moderate-to-severe Psoriasis in Adults: Update of the French Guidelines

Psoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis Pustular

France
LEO Pharma

Completed

Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation

Plaque Psoriasis | Psoriasis Vulgaris

Germany
Soligenix

Recruiting

Topical SGX302 for Mild-to-Moderate Psoriasis

Psoriasis | Plaque Psoriasis | Psoriasis Vulgaris

United States
ProgenaBiome

Recruiting

A Pilot Study to Explore the Role of Gut Flora in Psoriasis

Psoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Face | Psoriasis Nail | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis Geographica

United States
LEO Pharma

Terminated

Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab (COBRA)

Psoriasis | Plaque Psoriasis | Psoriasis Vulgaris

Belgium, Germany, Italy, Spain, Denmark, Austria, France, Greece, Switzerland, United Kingdom, Netherlands, Sweden
AstraZeneca
Parexel

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of AZD0284 in Healthy Subjects

Plaque Psoriasis Vulgaris

United Kingdom
AstraZeneca

Completed

Bioavailability of AZD0284 and IV Microtracer Study

Plaque Psoriasis Vulgaris

United Kingdom
PRCL Research Inc.

Completed

A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis

Plaque Psoriasis | Psoriasis Vulgaris

Canada, Slovakia, Ukraine
University of California, San Francisco

Terminated

Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis

Plaque Psoriasis | Psoriasis Vulgaris

United States
AstraZeneca

Terminated

Study to Determine if AZD0284 is Effective and Safe in Treating Plaque Psoriasis (DERMIS)

Plaque Psoriasis Vulgaris

Denmark
University of Alabama at Birmingham
Celgene

Completed

An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis

Psoriasis | Psoriasis Vulgaris | Psoriatic Nail

United States
UCB Biopharma SRL

Completed

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE READY)

Psoriatic Arthritis | Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, United Kingdom
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE VIVID)

Psoriatic Arthritis | Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Poland, Russian Federation, United Kingdom
University of Pennsylvania
Patient-Centered Outcomes Research Institute; University of Utah; National Psoriasis...

Completed

Light Treatment Effectiveness (LITE) Study (LITE)

Psoriasis | Psoriatic Plaque

United States
KoBioLabs

Active, not recruiting

A Study to Investigate Efficacy and Safety of KBL697 in Patients With Moderate Plaque Type Psoriasis

Psoriatic Plaque

United States, Australia
Novartis Pharmaceuticals

Completed

A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME) (SUPREME)

Plaque Type Psorisis

Italy
Novartis Pharmaceuticals

Active, not recruiting

Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP

Psoriasis Vulgaris | Pustular Psoriasis | Psoriatic Arthritis

Japan
Escalier Biosciences B.V.
Innovaderm Research Inc.

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Topical ESR-114 in Subjects With Plaque Psoriasis

Psoriatic Plaque

United States, Canada
Pantec Biosolutions AG

Unknown

Laser-assisted Topical Administration of Etanercept (Enbrel®) in Patients With Mild to Moderate Plaque-type Psoriasis

Psoriatic Plaque

Switzerland
Radboud University Medical Center
Sint Maartenskliniek

Completed

Discovery of Arthritis in Psoriasis Patients for Early Rheumatological Referral (DAPPER)

Psoriasis | Psoriasis Vulgaris | Psoriatic Arthritis | Psoriatic Nail

Netherlands
Novartis Pharmaceuticals

Completed

A Worldwide Survey on the Understanding of Psoriatic Disease Among Patients With Psoriasis and Psoriatic Arthritis

Plaque Psoriasis, Psoriatic Arthritis

Switzerland
Kyowa Kirin Co., Ltd.

Completed

A Phase 3 Clinical Study of KHK 4827

Psoriasis Vulgaris | Psoriatic Arthritis | Pustular; Psoriasis, Palmaris Et Plantaris | Psoriatic Erythroderma

Japan
Kyowa Kirin Co., Ltd.

Completed

A Phase 4 Clinical Study of Brodalumab

Psoriasis Vulgaris | Psoriatic Arthritis | Pustular; Psoriasis, Palmaris Et Plantaris | Psoriatic Erythroderma

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis

Plaque Psoriasis | Psoriatic Arthritis | Psoriatic Erythroderma | Pustular Psoriasis (Excluding a Localized)

Japan
Innovaderm Research Inc.
Ciusss de L'Est de l'Île de Montréal

Withdrawn

Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis

Psoriasis Vulgaris | Active Psoriatic Arthritis
Pfizer

Completed

Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)

Psoriasis Vulgaris | Pustular Psoriasis | Psoriasis Arthropathica | Erythrodermic Psoriasis

Japan
UCB Biopharma SRL

Recruiting

A Study to Evaluate the Efficacy, Safety, and Drug Concentration of Certolizumab Pegol (CZP) in Children and Adolescent Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO) (CIMcare)

Moderate Chronic Plaque Psoriasis | Severe Chronic Plaque Psoriasis | Mixed Guttate/Plaque Psoriasis

United States, Canada, Puerto Rico
University of Southern California

Completed

Impact of Decision-Framing in Psoriasis

Psoriasis | Psoriasis Vulgaris | Psoriatic Arthritis

United States
Egymedicalpedia

Not yet recruiting

Evaluation of TWEAK in Plaque Psoriasis and Psoriatic Arthritis Patients

Plaque Psoriasis

Egypt
selectION Therapeutics GmbH
FGK Clinical Research GmbH

Recruiting

A Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis

Psoriasis Vulgaris | Psoriatic Arthritis

Germany
Idera Pharmaceuticals, Inc.

Completed

Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis | Actively Extending Plaque Psoriasis

United States
Fresenius Kabi SwissBioSim GmbH
Merck KGaA, Darmstadt, Germany

Completed

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis (AURIEL-PsO)

Psoriasis | Moderate to Severe Plaque Psoriasis | Plaque Type Psoriasis

United States, Canada, Czechia, Hungary, Russian Federation, Bulgaria, Mexico, United Kingdom, Poland, Germany, Estonia, France
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE SURE)

Moderate to Severe Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Taiwan
Novartis Pharmaceuticals

Not yet recruiting

Modifying PEST for Psoriatic Arthritis Screening (ScreenX)

Plaque Psoriasis | Psoriatic Arthritis
Eli Lilly and Company

Active, not recruiting

A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India

Plaque Psoriasis | Psoriatic Arthritis

India
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE BRIGHT)

Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Taiwan, United Kingdom
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE RADIANT)

Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Belgium, Canada, France, Germany, Netherlands, Poland, Spain, Turkey, United Kingdom
Biocon Biologics Inc.
MEDA Pharma GmbH & Co. KG; Mylan Inc.; IQVIA Pvt. Ltd

Completed

Hulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and Immunogenicity

Moderate Chronic Plaque Psoriasis | Severe Chronic Plaque Psoriasis

Bulgaria, Czechia, Estonia, Poland
UCB Biopharma SRL

Completed

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)

Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Canada
UCB Biopharma SRL

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis (BE SHINING)

Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

China
Amgen

Completed

Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis

Psoriasis-Type Psoriasis | Plaque-Type Psoriasis

United States
Icahn School of Medicine at Mount Sinai
Bausch Health Americas, Inc.

Completed

Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis

Plaque Psoriasis | Palmoplantar Psoriasis

United States
AbbVie

Recruiting

Study to Evaluate the Effectiveness of Risankizumab in Participants With a Recent Diagnosis of Moderate Plaque Psoriasis in a Real-life Setting in Greece (REDEFINE)

Psoriasis | Moderate Plaque Psoriasis | Moderate Psoriasis

Greece
Chinese University of Hong Kong

Not yet recruiting

Shuiniujiao Dihuang Decoction With Variation for the Treatment of Psoriasis

Psoriasis Vulgaris
University Hospital, Ghent

Recruiting

Therapeutic Drug Monitoring of Risankizumab in Psoriasis Patients (BIOLOPTIM-RIS) (BIOLOPTIM-RIS)

Psoriasis Vulgaris

Belgium
University Hospital, Ghent

Recruiting

Therapeutic Drug Monitoring of Tildrakizumab in Psoriasis Patients (BIOLOPTIM-TIL)

Psoriasis Vulgaris

Belgium
University of California, San Francisco
Novartis Pharmaceuticals; National Psoriasis Foundation

Recruiting

Dermatologic Research Evaluation and Monitoring of Sleep in Moderate-to-Severe Psoriasis (DREAMS-PSO)

Psoriasis Vulgaris

United States
University of California, San Francisco
Sun Pharmaceutical Industries Limited

Recruiting

Predicting Inflammatory Skin Disease Response to IL-23 Blockade

Psoriasis Vulgaris

United States
Centre for Human Drug Research, Netherlands
Janssen Pharmaceuticals

Recruiting

An Explorative Psoriasis Biomarker Study

Psoriasis Vulgaris

Netherlands
University Hospital, Ghent
KU Leuven; University Ghent

Recruiting

Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO) (BIOLOPTIM-BRO)

Psoriasis Vulgaris

Belgium

Clinical Trials on Plaque Psoriasis Vulgaris

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations